[Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone].

Vestnik oftalmologii20015 citationsPMID: 11569188

Plain Language Summary

This clinical study evaluated Semax for treating glaucomatous optic neuropathy in patients with normalized intraocular pressure. The neuroprotective peptide showed therapeutic benefit in protecting optic nerve function even after pressure normalization, addressing the ongoing neurodegeneration component of glaucoma.

Abstract

A complex of neuroprotective therapy, including a new Russian neuropeptide semax, was used in the treatment of glaucoma patients with normalized ophthalmic tone. Electrophysiological and computer methods of examination demonstrated the advantages of new therapy over traditional neuroprotective treatment for glaucoma. The efficiency is due to pathogenetic activity of semax possessing both neuroprotective and neurotrophic effects.

Authors

Kurysheva, N I; Shpak, A A; Ioĭleva, E E; Galanter, L I; Nagornova, N D; Shubina, N Iu; Shlyshalova, N N